Background/Aim: Adaptive radiation therapy (ART) is a technique capable of reducing radiation dose to normal tissue without compromising local control. For potentially resectable thymoma, induction therapy is standard of care. Because large disease volume is common in this context, ART has been suggested to reduce toxicity from induction chemoradiation. This has not been previously illustrated in the literature. Case Report: A 38-year-old man with initially unresectable thymoma was treated with induction chemoradiation including cisplatin and etoposide. He received 45 Gy in 25 fractions and ART was utilized to shrink the radiotherapy field for the final 10 fractions. Results: Thymectomy showed Masaoka stage III disease with negative margins. He experienced no treatment-related toxicity and has no evidence of disease 8 years after diagnosis. Conclusion: Induction chemoradiotherapy with ART appears to be feasible, safe, and efficacious for locally advanced intact thymoma.

Original languageEnglish (US)
Pages (from-to)2467-2471
Number of pages5
JournalAnticancer Research
Issue number5
StatePublished - May 2021


  • Adaptive radiation therapy
  • Induction chemoradiation
  • Intact thymoma
  • Radiosensitive malignancy
  • WHO Type B2 thymoma
  • Cisplatin/therapeutic use
  • Humans
  • Etoposide/therapeutic use
  • Male
  • Combined Modality Therapy
  • Neoplasm Recurrence, Local/drug therapy
  • Adult
  • Thymoma/drug therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adaptive radiation therapy for intact thymoma: An illustrative report'. Together they form a unique fingerprint.

Cite this